Results 141 to 150 of about 334,436 (368)
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source
Optimized One-Dimensional SQIsign Verification on Intel and Cortex-M4
Transactions on Cryptographic Hardware and Embedded SystemsSQIsign is a well-known post-quantum signature scheme due to its small combined signature and public-key size. However, SQIsign suffers from notably long signing times, and verification times are not short either.
Marius A. Aardal +8 more
doaj +1 more source
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
Molecular Oncology, EarlyView.GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski +19 more
wiley +1 more source
On the (Im)possibility of Preventing Differential Computation Analysis with Internal Encodings
Transactions on Cryptographic Hardware and Embedded SystemsWhite-box cryptography aims at protecting implementations of cryptographic algorithms against a very powerful attacker who controls the execution environment. The first defensive brick traditionally embedded in such implementations consists of encodings,
Laurent Castelnovi, Agathe Houzelot
doaj +1 more source
Molecular Oncology, EarlyView.This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau +9 more
wiley +1 more source
Systematic generation of cryptographically robust S-boxes [PDF]
, 1993 Jennifer Seberry +2 more
openalex +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
Galois rings and algebraic cryptography [PDF]
, 1991 Javier Gomez-Calderon, Gary L. Mullen
openalex +1 more source